Compare SKYT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | NVCR |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | SKYT | NVCR |
|---|---|---|
| Price | $30.28 | $11.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $26.50 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.1M | 964.3K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | 21.79 |
| EPS | ★ 2.44 | N/A |
| Revenue | $442,139,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $40.16 | $7.72 |
| Revenue Next Year | $4.52 | $6.74 |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | ★ 29.18 | 8.28 |
| 52 Week Low | $6.99 | $9.82 |
| 52 Week High | $36.07 | $20.05 |
| Indicator | SKYT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 48.89 |
| Support Level | $29.80 | $10.72 |
| Resistance Level | $31.19 | $13.30 |
| Average True Range (ATR) | 1.18 | 0.58 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 34.42 | 52.35 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.